SAM
VIR icon

Smartleaf Asset Management’s Vir Biotechnology VIR Stock Holding History

Smartleaf Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-330
Closed -$2.21K – 2979
2025
Q1 		$2.21K Buy
330
+14
+4% +$124 ﹤0.01% 2446
2024
Q4 		$2.32K Sell
316
-133
-30% -$1.05K ﹤0.01% 2494
2024
Q3 		$3.38K Buy
449
+11
+3% +$96 ﹤0.01% 2293
2024
Q2 		$3.88K Buy
+438
New +$4.2K ﹤0.01% 1926

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smartleaf Asset Management's VIR Position: Q2 2025 in Review

Smartleaf Asset Management sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 330 shares — an estimated $2.21K sold.

Smartleaf Asset Management first reported a position in VIR in Q2 2024 and held it in 4 quarters. The position peaked at $3.88K in Q2 2024. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Smartleaf Asset Management reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Smartleaf Asset Management sold 330 Vir Biotechnology shares in Q2 2025, an estimated $2.21K.
  • Smartleaf Asset Management first reported a position in Vir Biotechnology in Q2 2024 and held it in 4 quarters.
  • Smartleaf Asset Management's Vir Biotechnology position peaked at $3.88K in Q2 2024.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Smartleaf Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.